Travel Vaccine Business Increases 30%

With international travel forecast to increase again in 2026, a group of innovative vaccines is showing positive trends.

Bavarian Nordic A/S today announced its preliminary, unaudited financial results for 2025, highlighting strong demand for its travel vaccines.

On February 12, 2026, the company confirmed that its Travel Health business exceeded its latest financial guidance, reporting a 30% increase compared to 2024.

The demand for its existing rabies and Tick-Borne Encephalitis vaccines continued to grow, with increases of 34% and 20%, respectively.

Additionally, the first-year sales of the chikungunya vaccine (VIMKUNYA®) reached DKK 85 million (approximately $13.4 million).

While the mosquito-transmitted chikungunya virus has affected over 100 countries since its emergence, the state of Florida is reporting numerious travel-related cases and even an unusual local case in early 2026.

These increases exceed the global international travel activity, which only increased by 4% from 2024 to 2025, according to data from UN Tourism.

Paul Chaplin, President and CEO of Bavarian Nordic, commented in a press release, "We are encouraged by these extraordinary results."

We remain, however, the leading provider to governments of mpox and smallpox vaccines to support their public health responses, whether during outbreaks or for long-term stockpiling, and we continue to build strong partnerships to expand the base business."

The unedited company press release is found at this link.